Rummaging through drops this morning, found Google has scrubbed this article, found on Duck Duck Go.
Experimental Drug Promises to Kill the Flu Virus in a Day
Even if drug lives up to claim, it likely won’t be available in U.S. until next year at earliest
As Americans suffer through the worst influenza outbreak in almost a decade, a Japanese drugmaker says it has developed a pill that can kill the virus within a day. But even if the experimental drug lives up to the claim, it likely won’t be available in the U.S. until next year at the earliest.
A late-stage trial on Japanese and American flu patients found that for the people who took the Shionogi 4507 -0.26% & Co. compound, the median time taken to wipe out the virus was 24 hours. That is much quicker than any other flu drug on the market, including Roche AG’s RHHBY 0.05% Tamiflu, which the trial showed took three times longer to achieve the same result. Quickly killing the virus could reduce its contagious effects, Shionogi said.
Also, Shionogi’s experimental drug requires only a single dose, while patients need to take two doses of Tamiflu a day, for five days.
Both Shionogi’s compound and Tamiflu take roughly the same amount of time to entirely contain flu symptoms, but Shionogi says its compound provides immediate relief faster.
Scientists at the Japanese company leveraged their work on a blockbuster anti-HIV drug to create the compound, which works differently from existing flu medicines. It blocks the flu virus from hijacking human cellular machinery, Chief Executive Isao Teshirogi said. Switzerland’s Roche has acquired the international license to distribute Shionogi’s experimental drug.
"The data that we’ve seen looks very promising,” said Martin Howell Friede, who leads the World Health Organization’s advisory on vaccines, including for influenza. “This could be a breakthrough in the way that we treat influenza.”
Shionogi said Japan’s drug regulator is fast-tracking its approval and could approve it for use in Japan as early as March. The regulator declined to comment. Roche and Shionogi say they will apply for U.S. approval this summer and Shionogi doesn’t expect a decision until next year.
Other players including Johnson & Johnson, AstraZeneca PLC and a startup backed by Merck & Co. are testing new compounds to treat influenza A, the most common flu strain. Shionogi’s candidate is furthest along and it says the compound can also treat B strains that infect humans too.
The U.S. has been hit by one of the worst flu epidemics in years, and transmissions are now the most intense since a pandemic in 2009….
Moar
https://www.wsj.com/articles/experimental-drug-promises-to-kill-the-flu-virus-in-a-day-1518264004
2018 article
>leveraged their work on a blockbuster anti-HIV drug to create the compound
Appears the Japanese were ahead of the game.
Go Fund Me Takes Down Fundraising Campaign For Litigation Over Vaccine Mandate
We previously discussed how GoFundMe has joined social media sites in censoring opposing viewpoints on subjects from critical race theory to vaccines to election fraud.
The site once offered a neutral site for those seeking to support others with similar views or interests.
The company now insists that it will only allow people to gather on the site if it believes their views are true and correct.
However, it was still surprising to see the site take down a fundraising account for litigation against vaccine mandates.
The effort of former nurse Jennifer Bridges was simply to get such matters before the courts, which can be the ultimate authority on what is “misinformation.”
GoFundMe however blocked people from contributing to the litigation.
Bridges is a former registered nurse at Houston Methodist hospital who was fired after refusing to comply with the hospital’s vaccine requirement. She raised more than $180,000 for her lawsuit before being shutdown under the company’s “misinformation” policy. …
https://www.zerohedge.com/political/go-fund-me-takes-down-fundraising-campaign-litigation-over-vaccine-mandate
He who fights with monsters should be careful lest he thereby become a monster. And if thou gaze long into an abyss, the abyss will also gaze into thee.
-
F. Nietzsche.